In summary, our results show that peripheral CD11b+Ly6G−Ly6C− MDCs and tumor F4/80+ TAMs play important roles in decreasing the efficacy of cancer therapies and targeting them may improve outcomes. This evidence concerns the gene ITGAM and neoplasm.